Seminars in Oncology
Volume 33 , Pages S15-S18 , October 2006

Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Second- and Third-Line Settings

  • Bruce J. Giantonio

      Affiliations

    • Dr Giantonio serves on the Genentech BioOncology speakers bureau and is a paid consultant to Genentech and Sanofi-Aventis.
    • Corresponding Author InformationAddress reprint requests to Bruce J. Giantonio, MD, 12 Penn Tower, 3400 Spruce St, Philadelphia, PA 19104, USA.

References 

  1. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer [erratum in Lancet 352:1634, 1998]. Lancet. 1998;352:1407–1412
  2. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21:807–814
  3. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol. 2003;21:2059–2069
  4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  6. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;16:3706–3712
  7. Giantonio BJ, Catalano PJ, Meropol NJ. High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol. 2005;23(suppl):1s;(abstr 2)
  8. Saltz LB, Lenz H, Hochster H. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. J Clin Oncol. 2005;23(suppl):248s;(abstr 3508)
  9. Emmanouilides C, Pegram M, Robinson R. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol. 2004;8(suppl 1):S50–S52
  10. Chen HX, Mooney M, Boron M. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). J Clin Oncol. 2004;22:249;(abstr 3515)
  11. National Cancer Institute. Bevacizumab (Avastin) for metastatic colorectal cancer. Available at: http://www.cancer.govt/newscenter/pressreleases/bevacizumab (Accessed July 19, 2006)

PII: S0093-7754(06)00314-9

doi: 10.1053/j.seminoncol.2006.08.003

Seminars in Oncology
Volume 33 , Pages S15-S18 , October 2006

Article Tools

* Image Usage & Resolution